US President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the governments Medicaid program ‍and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.“We were subsidizing the entire world. We’re not doing it anymore,” Trump said at a White House press conference, flanked by nine drugmaker executives.For all the latest headlines follow our Google News channel online or via the app.Mehmet Oz, the director of the Centers for Medicare and Medicaid Service, said Regeneron, Johnson & Johnson, and AbbVie would visit the White ⁠House after the holidays for the launch of the government’s TrumpRx website.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid program for low-income